Price (delayed)
$22.55
Market cap
$2.69B
P/E Ratio
18.04
Dividend/share
N/A
EPS
$1.25
Enterprise value
$2.25B
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK
There are no recent dividends present for CPRX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.